Table 1.
Cases of psoriasis patients with serious baseline comorbidities treated with apremilast.
| Case | Sex | Age | Comorbidity (diagnosis) | APR Dose | Bas PASI | Tx outcome | APR duration | AEs |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 69 | Prostate cancer (2013) | 30 mg bid | 10.3 | PASI50 week 16 | 53 (LOoE) | None |
| 2 | M | 76 | Lung tuberculosis (1968) | 30 mg bid | 9 | PASI50 week 16 | 52 (Lost to f/u) | None |
| 3 | M | 73 | Latent tuberculosis | 30 mg bid | 13.4 | PASI75 week 16 | 72 (LOoE) | None |
| 4 | M | 79a | Lung cancer (2015) | 30 mg bid | 15.9 | PASI50 not achieved | 21 (LAoE) | Abdominal pain |
| 5 | F | 65 | Breast cancer (2016), hepatitis B | 30 mg bid | 5.3 | PASI100 24 weeks | 35 (clear skin) | Dyspepsia |
| 6 | M | 63 | Hepatitis C and liver fibrosis | 30 mg bid | 6.7 | PASI50 week 16 | 37 (LOoE) | None |
| 7 | M | 44 | Hemodialysis (Stage 5 Chronic kidney disease – IgA nephropathy) | 30 mg od | 13.2 | PASI50 week 24 | 40 (LOoE) | None |
| 8 | F | 66 | Lung tuberculosis (1980) | 30 mg bid | 11.1 | PASI50 week 16 | 4 (AEs) | Headache |
| 9 | M | 33 | HIV positive (2011) (CD4+ 602 cells/mm3) | 30 mg bid | 15.8 | PASI75 week 16 | 149 (SoD) | None |
| 10 | M | 65 | Urinary bladder cancer (2015), Stage 2 chronic kidney disease | 30 mg bid | 9.1 | PASI50 week 16 | 31 (LOoE) | None |
| 11 | F | 56 | Cervical cancer (2013) | 30 mg bid | 10.8 | PASI75 week 24 | 154 (SoD) | None |
| 12 | M | 37 | HIV positive (2009) (CD4+ 590 cells/mm3) | 30 mg bid | 24.5 | PASI50 week 24 | 56 (SoD) | Transient nausea |
| 13 | M | 44 | HIV positive (2002) (CD4+ 550 cells/mm3) | 30 mg bid | 33.6 | PASI90q week 52 | 104 (SoD) | Transient diarrhea |
| 14 | M | 32 | HIV positive (2009) (CD4+ 702 cells/mm3) | 30 mg bid | 19.3 | PASI90 week 24 | 34 (SoD) | Transient diarrhea |
| 15 | M | 88 | Hepatitis B | 30 mg bid | 28.6 | PASI90 week 8 | 16 (SoD) | None |
AEs = adverse events; APR = apremilast; Bas = baseline; F = female; f/u = follow-up; HIV = human immunodeficiency; LAoE = lack of efficacy; LOoE = loss of efficacy; M = male; o.d. = once daily; PASI = Psoriasis Area and Severity Index;; bid = twice daily (bis in die); PASI50 = 50% reduction of baseline PASI; PASI75 = 75% reduction of baseline PASI; virus; PASI90 = 90% reduction of baseline PASI; SoD = still on drug; Tx = treatment.
a
Deceased.